NCT07226726PHASE1Recruiting
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
The Foundation for Orthopaedics and Regenerative Medicine
Start Date
1/1/2025
Completion Date
12/31/2028
Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Detailed Description
Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Patients will need a diagnosis of Congenital Myasthenic Syndrome by a licensed physician.
* Patients must be able to provide informed consent, or have a guardian who does.
* Patient must be able to travel to the site of treatment.
Exclusion Criteria:
* Patients will be excluded from the trial if they are pregnant or have active cancer (malignancy) at the screening consultation.
Interventions
BIOLOGICAL
AlloEx exosomes
Conditions
Congenital Myasthenic Syndrome
Locations
Prodromos Stem Cell Institute
Naples, Florida 34102
United States
Prodromos Stem Cell Institute
Irving, Texas 75039
United States
Medical Surgical Associates Center
St John's,
Antigua and Barbuda